Efficacy of High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Relapsed Medulloblastoma: A Report on The Korean Society for Pediatric Neuro-Oncology (KSPNO)-S-053 Study.
10.3346/jkms.2010.25.8.1160
- Author:
Jun Eun PARK
1
;
Joseph KANG
;
Keon Hee YOO
;
Ki Woong SUNG
;
Hong Hoe KOO
;
Do Hoon LIM
;
Hyung Jin SHIN
;
Hyoung Jin KANG
;
Kyung Duk PARK
;
Hee Young SHIN
;
Il Han KIM
;
Byung Kyu CHO
;
Ho Joon IM
;
Jong Jin SEO
;
Hyeon Jin PARK
;
Byung Kiu PARK
;
Hyo Seop AHN
Author Information
1. Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Recurrence;
Medulloblastoma;
Transplantation, Autologous;
Tandem;
Hematopoietic Stem Cell Transplantation
- MeSH:
Adolescent;
Cerebellar Neoplasms/drug therapy/mortality/*therapy;
Child;
Child, Preschool;
Combined Modality Therapy;
Disease-Free Survival;
Female;
*Hematopoietic Stem Cell Transplantation;
Humans;
Male;
Medulloblastoma/drug therapy/mortality/*therapy;
Neoplasm Recurrence, Local/drug therapy/mortality/*therapy;
Republic of Korea;
Salvage Therapy;
Transplantation, Autologous;
Young Adult
- From:Journal of Korean Medical Science
2010;25(8):1160-1166
- CountryRepublic of Korea
- Language:English
-
Abstract:
The efficacy and toxicity of high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) were investigated for improving the outcomes of patients with relapsed medulloblastoma. A total of 15 patients with relapsed medulloblastoma were enrolled in the KSPNO-S-053 study from May 2005 to May 2007. All patients received approximately 4 cycles of salvage chemotherapy after relapse. Thirteen underwent HDCT/ASCT; CTE and CM regimen were employed for the first HDCT (HDCT1) and second HDCT (HDCT2), respectively, and 7 underwent HDCT2. One transplant related mortality (TRM) due to veno-occlusive disease (VOD) occurred during HDCT1 but HDCT2 was tolerable with no further TRM. The 3-yr overall survival probability and event-free survival rates +/-95% confidence intervals (CI) were 33.3+/-12.2% and 26.7% +/-11.4%, respectively. When analysis was confined to only patients who had a complete response (CR) or partial response (PR) prior to HDCT, the probability of 3-yr overall survival rates +/-95% CI was 40.0+/-15.5%. No patients with stable disease (SD) or progressive disease (PD) survived. Survival rates from protocol KSPNO-S-053 are encouraging and show that tumor status prior to HDCT/ASCT is an important factor to consider for improving survival rates of patients with relapsed medulloblastoma.
